Mark R. Bamforth, Director at PEREGRINE PHARMACEUTICALS INC (PPHM), bought 98,500 shares at $4.48 ($444K) on 2017-10-27, disclosed to the SEC on 2017-10-27.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.48 | 200 | $895 | 0.2% |
| 2 | $4.48 | 200 | $896 | 0.2% |
| 3 | $4.49 | 4,993 | $22K | 5.0% |
| 4 | $4.49 | 1,800 | $8K | 1.8% |
| 5 | $4.49 | 1,800 | $8K | 1.8% |
| 6 | $4.49 | 201 |
| $902 |
| 0.2% |
| 7 | $4.49 | 300 | $1K | 0.3% |
| 8 | $4.49 | 4,993 | $22K | 5.1% |
| 9 | $4.49 | 5,340 | $24K | 5.4% |
| 10 | $4.49 | 201 | $903 | 0.2% |
| 11 | $4.49 | 5,340 | $24K | 5.4% |
| 12 | $4.51 | 35,966 | $162K | 36.5% |
| 13 | $4.51 | 35,966 | $162K | 36.6% |
| 14 | $4.51 | 1,200 | $5K | 1.2% |
| Total | $4.50 avg | 98,500 | $444K | 100% |
| Filing → |
| CDMO | BUY | 2020-03-16 | $104K | — | Filing → |
| CDMO | BUY | 2018-02-20 | $113K | — | Filing → |
| GENZ | BUY | 2009-03-06 | $38K | — | Filing → |